References | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

References

Filters: Author is P Y Kwo [Clear All Filters]

K

Kwo PY, Gane EJ, Peng C-Y, et al. Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial [P0886]. J Hepatol. 2015;62(Suppl 2):S674-S675.

Kwo PY, Gane EJ, Peng CY, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(1):164-175.e4.

Kwo PY, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64(2):370-380.

Top